Table 2.
Summary of cases.
| Characteristic | All cases (n = 72)∗ |
| Age (Yr) | |
| Average (range) | 63 (28–84) |
| Gender | |
| Male | 44 (61%) |
| Female | 28 (39%) |
| Tumor type | |
| Melanoma | 28 (39%) |
| NSCLC | 24 (33%) |
| Urothelial cancer | 4 (6%) |
| SCLC | 2 (3%) |
| Renal cell carcinoma | 2 (3%) |
| Other | 6 (8%) |
| Not reported | 6 (8%) |
| Past diabetes history | 7 (10%) |
| PD-1 inhibitor | |
| Nivolumab | 35 (49%) |
| Pembrolizumab | 22 (31%) |
| Atezolizumab | 5 (7%) |
| Durvalumab | 4 (6%) |
| Sintilimab | 1 (1%) |
| Not reported | 5 (7%) |
| Time or estimated time to DKA onset in weeks | |
| Median (range) | 9 (0.5–60) |
| HbA1c (%) | |
| Average (range) | 8.2 (5.4–13.1) |
| C-peptide | |
| Lower than normal range | 34 (47%) |
| Undetectable | 24 (33%) |
| Not reported | 13 (18%) |
| β-cell related autoantibodies | |
| Positive | 33 (46%) |
| Negative | 37 (51%) |
| Not reported | 2 (3%) |
| Other autoimmune endocrinopathy | |
| Thyroiditis | 14 (19%) |
| Hypophysitis | 2 (3%) |
| Addison disease | 1 (1%) |
∗
Include the present case.
DKA = diabetic ketoacidosis, HbA1c = glycated hemoglobin, NSCLC = non-small-cell lung cancer, SCLC = small cell lung cancer.